Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Astrazeneca (AZNCF) over the last 15 years, with Q4 2025 value amounting to -$1.5 billion.

  • Astrazeneca's Net Cash Flow fell 17200.97% to -$1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.4 billion, marking a year-over-year increase of 1104.36%. This contributed to the annual value of $4.4 billion for FY2025, which is 1104.36% up from last year.
  • Astrazeneca's Net Cash Flow amounted to -$1.5 billion in Q4 2025, which was down 17200.97% from $2.2 billion recorded in Q3 2025.
  • Astrazeneca's Net Cash Flow's 5-year high stood at $8.6 billion during Q2 2021, with a 5-year trough of -$8.1 billion in Q3 2021.
  • In the last 5 years, Astrazeneca's Net Cash Flow had a median value of $307.5 million in 2021 and averaged $643.6 million.
  • In the last 5 years, Astrazeneca's Net Cash Flow plummeted by 19169.68% in 2022 and then soared by 217357.14% in 2025.
  • Over the past 5 years, Astrazeneca's Net Cash Flow (Quarter) stood at $198.0 million in 2021, then crashed by 37.88% to $123.0 million in 2022, then surged by 502.44% to $741.0 million in 2023, then surged by 178.68% to $2.1 billion in 2024, then plummeted by 172.01% to -$1.5 billion in 2025.
  • Its last three reported values are -$1.5 billion in Q4 2025, $2.2 billion for Q3 2025, and $3.2 billion during Q2 2025.